Arecor Therapeutics (LSE:AREC) Common Stock : £0.31 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Common Stock?

Arecor Therapeutics's quarterly common stock stayed the same from Dec. 2022 (£0.31 Mil) to Jun. 2023 (£0.31 Mil) and stayed the same from Jun. 2023 (£0.31 Mil) to Dec. 2023 (£0.31 Mil).

Arecor Therapeutics's annual common stock increased from Dec. 2021 (£0.28 Mil) to Dec. 2022 (£0.31 Mil) but then stayed the same from Dec. 2022 (£0.31 Mil) to Dec. 2023 (£0.31 Mil).

Arecor Therapeutics Common Stock Historical Data

The historical data trend for Arecor Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Common Stock Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.03

0.28

0.31

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial					0.28	0.28	0.31	0.31	0.31

Arecor Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.